This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Bayer Healthcare LLC, Crispr Therapeutics Ag. Active years: 2023-2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
2 out of 790 
2 out of 86 
Years Active: 2023-2025
Title: Michael Biag Gamalinda: Innovator in RNA-Programmable Endonuclease Systems
Introduction
Michael Biag Gamalinda is a prominent inventor based in Leverkusen, Germany. He has made significant contributions to the field of genetic engineering, particularly in the development of RNA-programmable endonuclease systems. His innovative work has led to the filing of multiple patents, showcasing his expertise and dedication to advancing biotechnology.
Latest Patents
Michael Biag Gamalinda holds 2 patents related to RNA-programmable endonuclease systems. His first patent focuses on novel systems for targeting, editing, or manipulating DNA in a cell, utilizing synthetic RNA-guided nucleases (sRGNs) derived from small type II CRISPR Cas9 endonucleases. The second patent also addresses RNA-programmable endonuclease systems, detailing systems that comprise heterologous vectors encoding a SluCas9 nuclease and guide RNAs (gRNAs). These inventions are pivotal for genome editing and various applications in biotechnology.
Career Highlights
Throughout his career, Michael has worked with notable companies such as Bayer Healthcare LLC and Crispr Therapeutics AG. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research and development.
Collaborations
Michael has collaborated with talented individuals, including Andre Cohnen and Moritz Schmidt. These partnerships have fostered an environment of innovation and creativity, further enhancing the impact of his work in the biotechnology sector.
Conclusion
Michael Biag Gamalinda is a distinguished inventor whose work in RNA-programmable endonuclease systems has the potential to revolutionize genetic engineering. His patents and collaborations reflect his commitment to advancing the field and improving biotechnological applications.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile